Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial-Reference-Cited by-同舟云学术

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial

Published:2017-10-10 Issue:1 Volume:178 Page:114-123
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Langley R.G.¹,Tsai T.‐F.²,Flavin S.³,Song M.³,Randazzo B.³,Wasfi Y.³,Jiang J.³,Li S.³,Puig L.⁴

Affiliation:

1. Department of Dermatology Dalhousie University Halifax Nova Scotia Canada

2. Department of Dermatology National Taiwan University Hospital Taipei Taiwan

3. Dermatology Janssen Research & Development, LLC Spring House PA U.S.A.

4. Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona Barcelona Spain

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.15750

Reference23 articles.

1. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

2. Pathogenesis and therapy of psoriasis

3. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis

4. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis

5. IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage

Cited by 278 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses;Dermatology and Therapy;2024-09-12

2. Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial;Acta Dermato-Venereologica;2024-09-05

3. Newer Therapies in Rheumatology;Medical Clinics of North America;2024-09

4. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

5. Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience;Journal of Clinical Medicine;2024-08-31